Total Results: 106
We asked legislators, regulators, consumer advocates and health care experts to weigh in on a new report saying the timing is right for California to move away from bifurcated oversight and designate a single health insurance regulator.
According to a new analysis, California taxpayers could pay as much as $5.1 billion a year to treat hepatitis C patients in state-funded programs, adding fuel to some experts’ contention that expensive drugs may bankrupt the health system. We asked consumer advocates, insurers, state health officials and pharmaceutical manufacturers to weigh in on the issue.
Experts and stakeholders reflect on half a century of Medicaid as we approach the 50th anniversary of two national health programs.
We asked legislators, consumer advocates, employers and insurers to weigh in on a bill in the California Legislature that would prohibit large employers from offering workers “skinny” health plans in California.
We asked stakeholders and legislators to weigh in on a package of two dozen bills in the state Legislature aimed at improving the state’s support network for aging and long-term care.
We asked legislators, consumer advocates, hospital officials and academic experts to weigh in on two bills in the California Legislature dealing with community benefits provided by not-for-profit hospitals.
We asked legislators, physicians, nurses, religious leaders and consumer advocates to weigh in on a proposal in the state Legislature that would give terminally ill Californians the right to ask for medical help to end their lives.
We asked politicians, academics and consumer advocates how California should pay for the rising costs of providing health coverage for retired state workers.
We asked legislators, physicians, drug manufacturers, state officials and consumer advocates how best to deal with high rates of prescribing drugs to children in the state’s foster care program.
We asked stakeholders, researchers and consumer advocates to weigh in on new anti-inflationary tools such as payment limits for specific medical treatments and new rules for containing prescription drug spending.